KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBT: 2017-2025

Historic EBT for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to -$5.2 million.

  • Amneal Pharmaceuticals' EBT fell 133.87% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.7 million, marking a year-over-year increase of 155.75%. This contributed to the annual value of -$55.0 million for FY2024, which is 36.61% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported EBT of -$5.2 million as of Q3 2025, which was down 110.10% from $51.7 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' EBT ranged from a high of $51.7 million in Q2 2025 and a low of -$232.7 million during Q2 2022.
  • Its 3-year average for EBT is -$1.0 million, with a median of $15.4 million in 2024.
  • The largest annual percentage gain for Amneal Pharmaceuticals' EBT in the last 5 years was 953.07% (2023), contrasted with its biggest fall of 990.28% (2023).
  • Over the past 5 years, Amneal Pharmaceuticals' EBT (Quarterly) stood at -$16.3 million in 2021, then skyrocketed by 53.09% to -$7.7 million in 2022, then tumbled by 990.28% to -$83.5 million in 2023, then surged by 81.65% to -$15.3 million in 2024, then slumped by 133.87% to -$5.2 million in 2025.
  • Its EBT was -$5.2 million in Q3 2025, compared to $51.7 million in Q2 2025 and $37.5 million in Q1 2025.